COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 273: Articles 2721-2730  | Next

A Systematic Review of the Attitude, Beliefs, and Acceptance of COVID-19 Vaccine in the Western and Eastern Hemisphere.
Chander, S., Kumari, R., Luhana, S.
10.1101/2023.11.08.23298274 — Posted: 2023-11-09
Real-world effectiveness of non-pharmaceutical interventions in containing COVID-19 pandemic after the roll-out of coronavirus vaccines: A systematic review
Xiaona, H., Chen, H., Zhu, X., Gao, W.
10.1101/2023.11.07.23297704 — Posted: 2023-11-08
Combining genomic data and infection estimates to characterize the complex dynamics of SARS-CoV-2 Omicron variants in the United States
Lopes, R., Pham, K., Klaassen, F., Chitwood, M. H., Hahn, A., Redmond, S., Swartwood, N. A., Salomon, J. A., Menzies, N. A., Cohen, T., Grubaugh, N. D.
10.1101/2023.11.07.23298178 — Posted: 2023-11-08
Small Fiber Neuropathy after COVID-19: A Key to Long COVID
McAlpine, L., Zubair, A., Joseph, P., Spudich, S.
10.1101/2023.11.07.23297764 — Posted: 2023-11-08
The impact of SARS-CoV-2 variants on the likelihood of children identified as sources of infection in the NIH workforce: a cohort study
van Loben Sels, J. M., Bailin, H. B., Bell, M. R., McCormick-Ell, J., McGann, M., Das, S., Roder, A. E., Ghedin, E., Castel, A. D., D. Rebecca, P., Kwan, J. L.
10.1101/2023.11.07.23297422 — Posted: 2023-11-08
Standardization and Comparison of Emergency Use Authorized COVID-19 Assays and Testing Laboratories
Rao, A., Lin, J. S., Parsons, R. S., Greenleaf, M., Westbrook, A., Lai, E., Bowers, H., McLendon, K. B., O'Sick, W. H., Baugh, T., Sifford, M., Sullivan, J., Lam, W. A., Bassit, L.
10.1101/2023.11.08.23297633 — Posted: 2023-11-08
Nanoscale cellular organization of viral RNA and proteins in SARS-CoV-2 replication organelles
Andronov, L., Han, M., Zhu, Y., Roy, A. R., Barentine, A. E. S., Garhyan, J., Qi, L. S., Moerner, W. E.
10.1101/2023.11.07.566110 — Posted: 2023-11-08
Universal protection against SARS-CoV-2 viruses by multivalent mRNA vaccine in mice
Lei, Z., Bian, S., Zhai, S., Yuan, X., Wang, R., Wang, P., Pandey, V., Zhang, C. Y., Yu, D., Chen, Z., Qin, P.
10.1101/2023.11.05.565350 — Posted: 2023-11-08
Predicting human and viral protein variants affecting COVID-19 susceptibility and repurposing therapeutics
Waman, V. P., Ashford, P., Lam, S. D., Sen, N., Abbasian, M., Woodridge, L., Goldtzvik, Y., Bordin, N., Wu, J., Sillitoe, I., Orengo, C.
10.1101/2023.11.07.566012 — Posted: 2023-11-08
Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
Oliveira, A. S. F., Kearns, F. L., Rosenfeld, M. A., Casalino, L. F., Berger, I., Schaffitzel, C., Davidson, A. D., Amaro, R. E., Mulholland, A. J.
10.1101/2023.11.06.565757 — Posted: 2023-11-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).